This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| FK506-binding protein 5 | |
|---|---|
| Name | FK506-binding protein 5 |
| Other names | FKBP51 |
| Uniprot | P60484 |
| Organism | Homo sapiens |
FK506-binding protein 5 is a human immunophilin encoded by the FKBP5 gene that modulates steroid receptor complexes and protein folding. It interacts with chaperones and signaling kinases to influence cellular responses to stress, metabolism, and neuroendocrine regulation. FKBP5 has been studied across genetics, endocrinology, psychiatry, and pharmacology for its role in glucocorticoid receptor function and disease susceptibility.
FKBP5 was identified through biochemical characterization of FK506-binding proteins during investigations by laboratories associated with Howard Hughes Medical Institute, National Institutes of Health, and academic centers such as Harvard University and University of California, San Francisco. Early reports linked FKBP5 to immunosuppressants like Tacrolimus (FK506) and to chaperone systems including Heat shock protein 90 and Hsp70. Subsequent genetic, clinical, and structural studies from groups at institutions like Max Planck Society, Karolinska Institute, and Stanford University School of Medicine established FKBP5 as a regulator of the glucocorticoid receptor pathway and a candidate gene in stress-related disorders investigated by consortia including the Psychiatric Genomics Consortium.
FKBP5 encodes a 51-kDa protein containing two FK506-binding (FKBP) domains and a tetratricopeptide repeat (TPR) domain that mediates interactions with Hsp90 and co-chaperones characterized in structural studies from labs at European Molecular Biology Laboratory and Riken. High-resolution crystallography and cryo-EM efforts from teams at University of Cambridge and Massachusetts Institute of Technology revealed conformational states that affect peptidyl-prolyl isomerase activity and client protein binding similarly examined in analyses by researchers at MRC Laboratory of Molecular Biology. Biochemical assays employing mutagenesis from investigators at Cold Spring Harbor Laboratory mapped residues essential for isomerase catalysis and for docking to steroid receptor complexes studied in works from Johns Hopkins University and University College London.
FKBP5 expression is tissue-specific and inducible; transcriptomic surveys from projects like ENCODE and GTEx show high FKBP5 mRNA in brain regions such as the hippocampus and amygdala, in peripheral tissues including adipose tissue and liver, and in immune cells profiled by groups at Sanger Institute and Broad Institute. Transcriptional control involves glucocorticoid response elements elucidated by laboratories at Yale University and Columbia University, with epigenetic modulation (DNA methylation) reported in cohort studies conducted by teams at McGill University and Karolinska Institute. FKBP5 is also regulated post-transcriptionally by microRNAs examined in collaborative studies at University of Oxford and by proteostasis networks involving ubiquitin ligases characterized at École Normale Supérieure.
FKBP5 participates in folding and trafficking of steroid receptors, as demonstrated in functional studies from Scripps Research and University of Pennsylvania. By modulating glucocorticoid receptor sensitivity, FKBP5 influences processes studied by endocrinology groups at Mayo Clinic and Cleveland Clinic including metabolic regulation and immune responses observed in clinical cohorts from Imperial College London. FKBP5 also affects intracellular signaling cascades such as AKT and MAPK pathways reported by researchers at Weizmann Institute of Science and Rockefeller University, impacting cellular proliferation, apoptosis, and synaptic plasticity explored in neuroscience research at MIT, Columbia University, and Duke University.
FKBP5 is a key modulator of the hypothalamic–pituitary–adrenal (HPA) axis investigated in seminal work from groups at Max Planck Institute of Psychiatry and National Institute of Mental Health. It acts as an intracellular regulator that desensitizes glucocorticoid receptor signaling after stress exposure, a mechanism characterized in animal models developed at Cold Spring Harbor Laboratory and behavioral studies at University of Cambridge. Human genetic and longitudinal cohort studies by consortia including ENIGMA and clinical centers such as King’s College London linked FKBP5 allelic variants to differential cortisol dynamics and to stress-related phenotypes measured in trials at Stanford University School of Medicine.
Variants and epigenetic alterations in FKBP5 have been associated with psychiatric disorders including major depressive disorder, post-traumatic stress disorder, and bipolar disorder in large-scale studies by the Psychiatric Genomics Consortium and research groups at Yale University and University College London. FKBP5 dysregulation has been implicated in metabolic syndromes explored at Imperial College London and in oncogenesis described in studies from Johns Hopkins University and University of Texas MD Anderson Cancer Center. Associations with inflammatory and autoimmune conditions have emerged from work at University of Michigan and Karolinska Institute, and FKBP5 methylation patterns predict treatment response in trials coordinated by Vanderbilt University and Massachusetts General Hospital.
FKBP5 is a prospective pharmacological target; small molecules and peptide inhibitors have been developed by teams at GlaxoSmithKline, Pfizer, and academic labs at University of Zurich and ETH Zurich to modulate its isomerase activity or disrupt protein–protein interactions with Hsp90 and steroid receptors. Repurposing of immunosuppressants such as Tacrolimus informed early inhibitor design, while high-throughput screens performed at Novartis and Roche identified lead compounds that affect stress-related behaviors in preclinical models from Scripps Research. Clinical translation efforts and precision-medicine strategies integrating FKBP5 genotyping are underway in multicenter trials coordinated by institutions like Mayo Clinic and NIH Clinical Center.
Category:Proteins